Skip to content
Use case · Briefing Documents

Briefing packages that anticipate the questions.

Asthra drafts Pre-IND and Advisory Committee briefing documents — assembling nonclinical, CMC, and clinical evidence into a benefit-risk narrative. Every position on an FDA question is backed by a claim you can trace to its source, so the package holds up under scrutiny.

Briefing draft in progress
Compound-XYZ-ODAC-Briefing.docx
2.1Indication & Unmet Need512 wordsDone
8Clinical Pharmacology438 wordsDone
10.2Primary Endpoint Analysis694 wordsDone
11.1Integrated Safety1 gap
12Benefit-Risk AssessmentDrafting
2.5Positions on Voting QuestionsPending
Pre-IND + AdCom
Type B meeting packages through to ODAC/VRBPAC briefing documents.
Integrated
Safety and efficacy synthesised across the whole development program.
100%
Of positions backed by claims that trace to source.
What's new
For briefing packages, the studio capabilities that matter most are tables & figures in the chat for the integrated safety and efficacy analyses, and reviewer personas — run an FDA Clinical Reviewer over your positions before the agency does.
Inputs

What you bring to the draft.

Asthra assembles the package from the evidence your program has generated.

PDF

Nonclinical Summary

Pharmacology and toxicology — for the Pre-IND nonclinical section and the starting-dose justification.

XLS

Integrated Safety Database

Pooled adverse-event tables and exposure-adjusted rates for the integrated safety section.

XLS

Integrated Efficacy Analyses

Primary and secondary endpoints across trials — the basis for the efficacy narrative.

PDF

Prior Meeting Minutes

FDA feedback and prior interactions, so the package addresses what the agency already raised.

DOC

FDA Voting Questions

The questions the package must answer — each mapped to a position and its supporting evidence.

DOC

CMC Summary

Chemistry, manufacturing, and controls for the CMC overview section.

Workflow

From the program evidence
to a briefing package.

01

Upload & classify

Drop your nonclinical summary, integrated safety and efficacy data, prior minutes, and voting questions into the project. Asthra classifies and indexes each.

02

Approve the plan

Asthra proposes the package structure — Pre-IND or AdCom — and maps each FDA question to the evidence that answers it. Approve once.

03

Generate the first draft

Asthra computes integrated analyses with auditable Python, drafts the benefit-risk narrative, and proposes positions on each voting question. Gaps flag where the evidence is thin.

04

Writer review in Word

Refine the benefit-risk argument, regenerate a pooled-safety table, or run an FDA reviewer persona over your positions in the task pane. Every change is logged.

05

Hand off for sign-off

The package ships with the audit ledger embedded — every position traces to the analysis and the source data behind it.

Manual vs. Asthra

What changes for the regulatory team.

Manual briefing drafting

  • Integrated safety and efficacy assembled by hand across many study reports
  • Benefit-risk narrative synthesised from thousands of records under deadline
  • Positions on FDA questions argued without a clean evidence trail
  • Pooled tables rebuilt manually for each package
  • Consistency with prior FDA interactions tracked by memory

Briefing drafting with Asthra

  • +Integrated analyses computed with deterministic, auditable Python
  • +Benefit-risk narrative grounded in the cited evidence base
  • +Each position mapped to the claims and sources that support it
  • +Pooled tables generated from source data, reproducible
  • +Prior interactions carried forward as structured state

Pilot Asthra
on a real briefing package.

30-day pilot. Bring one program. We'll match Asthra's briefing package against your existing process — section by section.